The transition from NAFLD to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) isn’t just a linguistic update—it’s a paradigm shift. By including “Metabolic Dysfunction” in the name, we are finally acknowledging that liver fat is a systemic symptom of metabolic syndrome, rather than an isolated “liver issue.”
The Clinical Deep-Dive:
-
Metabolic Markers: A diagnosis now requires at least one of five cardiometabolic risk factors, such as insulin resistance or elevated blood pressure.
-
The “Silent” Progression: Simple steatosis can rapidly transition to MASH (the replacement for NASH), leading to irreversible fibrosis.
-
Proactive Screening: With the rise of MASLD, we must look beyond AST/ALT levels and focus on the FIB-4 index for earlier detection of scarring.
Further Reading:
With MASLD now linked so closely to cardiovascular events, should we be treating “fatty liver” as an early-stage warning for heart disease?
MBH/PS